An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients

Exclusion Criteria

• •Patients with heme positive stool at screening. Patients with heme positive stool that can be attributed to hemorrhoids or anal fissures are eligible for inclusion.
• •Patients with hypo- or hyperthyroidism as determined by history, or screening TSH results.
• •Patients with known or suspected perforation or obstruction.
• •History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy.
• •Patients with a known history of organic cause for their constipation.
• •Patients meeting the ROME definition of Irritable Bowel Syndrome
• •Patients currently taking any of the following medications that are known to effect bowel habits:
• •* Antidiarrheals
• •* Antacids containing magnesium or aluminum salts
• •* Anticholinergics
• •* Antispasmodic agents
• •* Erythromycin and other macrolides
• •* Octreotide
• •* Lotronex, Zofran, or other 5-HT3 antagonists
• •* Zelnorm, or other 5-HT4 agonists
• •* Opiods/narcotic analgesics
• •* Prokinetics
• •* Serotonin re-uptake inhibitors or tricyclic antidepressants
• •* Calcium antagonists
• •Patients who are breastfeeding, pregnant, or intend to become pregnant during the study.
• •Female patients of childbearing potential who refuse a pregnancy test.
• •Patients with a known allergy to polyethyleneglycol.
• •Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
• •Patients who, within the past 30 days have participated in an investigational clinical study